Nebraska Medicaid does not cover Wegovy or Zepbound for weight loss

Nebraska Medicaid does not cover drugs for weight loss: its state plan lists weight-loss agents among the excluded drug classes, covering that class only for weight gain. It covers Wegovy only to lower the risk of major cardiovascular events or for MASH, and Zepbound only for moderate-to-severe obstructive sleep apnea, each with prior authorization. Heritage Health managed care plans must follow the same preferred drug list.12349

Nebraska Medicaid has no prior authorization path for weight loss alone. Its Wegovy and Zepbound forms cover only the cardiovascular, MASH and sleep apnea uses, and each requires a completed medically supervised weight management program.3456

• Wegovy, cardiovascular path (injection or tablets): adults 45 to 74, a baseline BMI of 30 or more, or 27 or more with at least one weight-related condition, a documented prior heart attack, stroke or symptomatic peripheral arterial disease, no diabetes and no A1C of 6.5% or more, at least 6 months of a medically supervised weight management program with counseling, and continued diet, activity and cardiovascular medication adherence. First approval lasts 6 months; renewal (12 months) needs at least 5% weight loss or keeping that loss.
• Wegovy, MASH path (injection only): adults 18 or older with MASH and F2 or F3 fibrosis confirmed by elastography, an ELF test or a biopsy, at least 6 months of a medically supervised weight management program, prescribed by or with an endocrinologist, gastroenterologist or hepatologist; members with type 2 diabetes are asked whether Ozempic was tried. First approval lasts 6 months, renewal 12 months.
• Zepbound, sleep apnea path: adults 18 or older with moderate-to-severe obstructive sleep apnea (AHI, RDI or REI of 15 or more on a sleep study), a baseline BMI of 30 or more, no diabetes and no A1C of 6.5% or more, at least 6 months of a medically supervised weight management program, documented failure, intolerance or ineligibility for PAP or oral appliance treatment, and a sleep specialist prescribing or consulted.
• All three paths: no other GLP-1 receptor agonist or DPP-4 inhibitor at the same time.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults 45 to 74 with established cardiovascular disease, without diabetes (injection or tablets): Covered with prior authorization35
• Wegovy (injection), noncirrhotic MASH with F2 or F3 liver fibrosis in adults (injection): Covered with prior authorization36
• Zepbound, moderate-to-severe obstructive sleep apnea in adults 18 or older with a BMI of 30 or more: Covered with prior authorization4

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Nebraska Medicaid announcement that Nebraska has joined.12

The State of Nebraska's employee health plan, provided through Blue Cross and Blue Shield of Nebraska, does not cover diet, weight-loss or appetite-suppressant drugs under its prescription drug program, according to its summary plan description for the plan year starting July 1, 2026.1314

Pharmacy benefit: Blue Cross and Blue Shield of Nebraska (medical); Prime Therapeutics (prescription drugs, retained by BCBSNE).

Marketplace (ACA) plans: Nebraska's essential health benefits benchmark plan, a Blue Cross and Blue Shield of Nebraska small-group plan (BluePride Plus), excludes weight-loss, diet and appetite-suppressant drugs.19

On the November 2026 preferred drug list (updated Nov. 2, 2026), Ozempic injection, Trulicity and Victoza are preferred, and Mounjaro and Ozempic tablets are non-preferred. Preferred drugs need a type 2 diabetes diagnosis and a trial of metformin (or a diagnosis of ASCVD with type 2 diabetes); non-preferred drugs need trials of two preferred drugs, an A1C of 7 or more and a metformin trial. Rybelsus was non-preferred through the October 2026 list and does not appear in the November 2026 list.78

In 2025, Nebraska Medicaid paid for 37,205 GLP-1 prescriptions, $36.1 million before rebates: 18 per 1,000 residents, against 32 across the states and DC, 35th of 51.66 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 22 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4142323328362131

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2829302136373839403534
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.232521

In 2024, Medicare Part D drug plans paid for 127,225 GLP-1 claims from prescribers in Nebraska, $143.2 million in total drug cost.67

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.71 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Nebraska on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7273 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by Nebraska’s board of pharmacy or attorney general on their own sites.

The FDA’s register lists 1 outsourcing facilities (503B) in Nebraska, as of November 6, 2026; 0 show no inspection date and 1 were issued a Form 483.68